- Projects & figures
- News & Events
- Managing your project
- About ERC
Multifunctional nanoparticles being developed by EU-funded researchers are set to revolutionise treatments for complex bone diseases, enabling novel therapies for hundreds of millions of people worldwide suffering from bone cancer, bacterial bone infections and osteoporosis.
Space has a wealth of resources for humanity. Scientific missions enable new discoveries and increase knowledge of our solar system. Satellites orbiting around the Earth provide us with a broad range of services for telecommunications, weather forecasting, marine and air traffic, forest mapping, etc. However, intense space activity comes at a cost both in terms of energy consumption and dangerous space debris produced.
Dr Málnási-Csizmadia focuses on enzymes, proteins essential for body functions, and the largely unexplored intricate mechanisms underlying their activity. His recent findings could open the way to a ground-breaking development in pharmacology, especially in targeted cancer therapy.
For the first time ever, two ERC grantees, Prof. Luca G. Guidotti and Dr Matteo Iannacone, have observed in vivo how specific white blood cells, so-called cytotoxic T lymphocytes, identify, target and attack liver cells that are infected with the hepatitis B virus. To witness these immune cells in action in real time, the two scientists developed advanced, dynamic imaging techniques. An estimated 240 million people are chronically infected with hepatitis B worldwide. This discovery, published today in the scientific journal Cell, opens new horizons for the development of novel therapies.